Successful Treatment with Secukinumab in an Erythrodermic Psoriasis Patient with End-Stage Kidney Disease on Hemodialysis: A Case Report

一例接受血液透析的终末期肾病合并红皮病型银屑病患者成功接受司库奇尤单抗治疗的病例报告

阅读:1

Abstract

Patients with erythrodermic psoriasis (EP) complicated by end-stage renal disease (ESRD) requiring hemodialysis are extremely rare in clinical practice, and treatment options for this specific population remain highly limited. Herein we report a case of an EP patient with ESRD, in whom treatment with an interleukin-17 (IL-17) inhibitor secukinumab not only rapidly alleviated erythrodermic symptoms but also resulted in a certain degree of improvement in renal function. At the 7-month follow-up, the patient maintained skin lesion clearance with no deterioration in renal function-a finding that has not been consistently documented in previous literature. This case suggests that for patients with psoriasis complicated by kidney disease IL-17 inhibitors may serve as a potentially favorable therapeutic option.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。